Hing C. Wong

Best Publications

• Enhancing T cell therapy through TCR-signaling-responsive nanoparticle drug delivery

  Li Tang;Yiran Zheng;Mariane Bandeira de Melo;Llian Mabardi

  615
  Citations

• T cell sensing of antigen dose governs interactive behavior with dendritic cells and sets a threshold for T cell activation

  Sarah E Henrickson;Thorsten R Mempel;Irina B Mazo;Bai Liu

  504
  Citations

• A soluble single-chain T-cell receptor IL-2 fusion protein retains MHC-restricted peptide specificity and IL-2 bioactivity.

  Kimberlyn F. Card;Shari A. Price-Schiavi;Bai Liu;Elizabeth Thomson

  484
  Citations

• ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial

  John M Wrangle;Vamsidhar Velcheti;Manish R Patel;Elizabeth Garrett-Mayer

  426
  Citations

• First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation

  Rizwan Romee;Sarah Cooley;Melissa M. Berrien-Elliott;Peter Westervelt

  411
  Citations

• CD56bright NK cells exhibit potent antitumor responses following IL-15 priming.

  Julia A. Wagner;Maximillian Rosario;Rizwan Romee;Melissa M. Berrien-Elliott

  320
  Citations

• IL-15:IL-15 receptor alpha superagonist complex: High-level co-expression in recombinant mammalian cells, purification and characterization

  Unknown

  301
  Citations

• Efficacy and Mechanism-of-Action of a Novel Superagonist Interleukin-15: Interleukin-15 Receptor αSu/Fc Fusion Complex in Syngeneic Murine Models of Multiple Myeloma

  Unknown

  263
  Citations

• Comparison of the Superagonist Complex, ALT-803, to IL15 as Cancer Immunotherapeutics in Animal Models

  Peter R. Rhode;Jack O. Egan;Wenxin Xu;Hao Hong

  228
  Citations

• Structural basis of the recognition of the dishevelled DEP domain in the Wnt signaling pathway.

  Hing C. Wong;Junhao Mao;Jason T. Nguyen;Shamala Srinivas

  214
  Citations

• Novel human interleukin-15 agonists.

  Unknown

  211
  Citations

• Latent HIV reservoirs exhibit inherent resistance to elimination by CD8+ T cells

  Szu Han Huang;Yanqin Ren;Allison S. Thomas;Dora Chan

  201
  Citations

• Phase I Trial of ALT-803, A Novel Recombinant IL15 Complex, in Patients with Advanced Solid Tumors.

  Kim Margolin;Chihiro Morishima;Chihiro Morishima;Vamsidhar Velcheti;Jeffrey S. Miller

  200
  Citations

• IL-15 superagonist/IL-15RαSushi-Fc fusion complex (IL-15SA/IL-15RαSu-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8+ T cells, and mediates potent anti-tumor activity against murine breast and colon carcinomas

  Peter S. Kim;Anna R. Kwilas;Wenxin Xu;Sarah Alter

  188
  Citations

• A Subset of Latency-Reversing Agents Expose HIV-Infected Resting CD4+ T-Cells to Recognition by Cytotoxic T-Lymphocytes.

  R. Brad Jones;R. Brad Jones;Stefanie Mueller;Rachel O’Connor;Katherine Rimpel

  187
  Citations

• IL-15 super-agonist (ALT-803) enhances natural killer (NK) cell function against ovarian cancer.

  M. Felices;S. Chu;B. Kodal;L. Bendzick

  160
  Citations

• The IL-15-Based ALT-803 Complex Enhances FcγRIIIa-Triggered NK Cell Responses and in Vivo Clearance of B Cell Lymphomas

  Maximillian Rosario;Bai Liu;Lin Kong;Lynne I. Collins

  156
  Citations

• Safety and virologic impact of the IL-15 superagonist N-803 in people living with HIV: a phase 1 trial

  Unknown

  143
  Citations

• Antibody-Dependent Cellular Cytotoxicity against Primary HIV-Infected CD4+ T Cells Is Directly Associated with the Magnitude of Surface IgG Binding

  Adjoa Smalls-Mantey;Nicole Doria-Rose;Rachel Klein;Andy Patamawenu

  143
  Citations

• Glycolytic requirement for NK cell cytotoxicity and cytomegalovirus control

  Annelise Y. Mah;Armin Rashidi;Molly P. Keppel;Nermina Saucier

  125
  Citations